Founded in 2012, EcoR1 Capital is a venture capital firm based in San Francisco, California. The firm focuses on investing in the healthcare, life sciences, and oncology sectors, aiming to support and drive advancements in these vital areas.
Oleg Nodelman is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm established in 2013. With over twenty years of experience in biotech investing, Mr. Nodelman excels in all aspects of investment management and maintains deep connections within the biotech and scientific communities. Before founding EcoR1, he served as a portfolio manager at BVF Partners, a pioneering hedge fund dedicated to the biotechnology sector. He holds a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University.
EcoR1 Capital is a hedge fund managing discretionary assets totaling $5,001,741,440 for 5 clients, as reported in their Form ADV on March 28, 2024. Their most recent 13F filing for Q1 2024 disclosed $3,953,710,314 in managed 13F securities, with a top 10 holdings concentration of 61.14%. The fund's largest holding is Apellis Pharmaceuticals Inc., with 11,357,425 shares.
| Fund Name: | EcoR1 Capital |
| Manager | Oleg Nodelman |
| Portfolio Value | $1,686,022,983 |
| Change This QTR | +0.64% |
| No. | Security | Ticker | Shares | Value | Activity | % Port | History |
|---|---|---|---|---|---|---|---|
| 1. | APLS | 11,895,808 | $260,161,321 | +1% | 15.43% | ||
| 2. | JAZZ | 1,706,469 | $211,858,126 | 12.57% | |||
| 3. | Zymeworks Inc | 17,259,548 | $205,561,217 | +15% | 12.19% | ||
| 4. | ANAB | 7,880,094 | $146,490,947 | +1% | 8.69% | ||
| 5. | CRNX | 4,288,120 | $143,823,545 | 8.53% |
| Symbol | Company | Filed By | Filing Date | Filing |
|---|---|---|---|---|
| 2025-06-27 | ||||
| 2025-05-29 | ||||
| 2025-05-19 | ||||
| 2025-05-16 | ||||
| 2025-05-15 |
